Tuesday, August 6, 2019 | 4:15 - 5:30 pm
Harbor II & III
PANEL DISCUSSION: Next-Generation Immunotherapies
CHI’s Immuno-Oncology Summit brings you the latest advances in immunotherapy every year. This panel of industry thought leaders will discuss the technology advances and implementation strategies for next-generation immunotherapies, including emerging
immunotherapy combinations, bispecific antibodies, oncolytic virotherapy, adoptive cell therapy, personalized vaccines and neoantigen targeted therapies, small molecules and ADCs, cytokines, and innate immunity targeted therapies.
Pamela Carroll, PhD
Senior Vice President, Immuno-Oncology, Genocea Biosciences
PhD, DABT, President & CEO, Bionavigen
Tara Arvedson, PhD
Director, Oncology Research, Amgen
Michael A. Curran, PhD
Associate Professor, MD Anderson Cancer Center; President, Immunogenesis, Inc.
Raymond Tesi, MD
CEO/CMO, INmune Bio
David Kirn, MD
Co-Founder & Executive Chairman, IGNITE Immunotherapy
Thursday, August 8, 2019 | 8:25 - 9:30 am
PANEL DISCUSSION: Partnering and Licensing in Immuno-Oncology
Big pharma and biotech are under pressure to compete in the booming Immuno-Oncology market and to capitalize on new technologies and innovations to bring next-generation immunotherapies to the patients. This insider panel will share what they look for
in a partner or investment, and discuss opportunities for collaboration or in-licensing of novel immunotherapies, IO targets or biomarkers, and potential combination therapies.
Melinda Griffith, JD
Chief Legal Counsel and Vice President, Strategic Alliances
Michael Woo, MBA
Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.
Kathryn McCabe, PhD
Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company
Scott M. DeWire, PhD
Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.
Philip Arlen, MD
President & CEO, Precision Biologics
Stephen Doberstein, PhD
Senior Vice President, R&D and Chief Research and Development Officer, Nektar Therapeutics